Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, and Shoreline Biosciences, a biotechnology company developing allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer, have formed an alliance to advance the future of iPSC-derived cellular therapies.
 
The alliance leverages Dendreon’s extensive manufacturing, process development and end-to-end logistics expertise for the advancement of Shoreline’s pipeline of iPSC-derived cellular therapies. Dendreon is providing scalable cGMP manufacturing support for certain programs through clinical development and launch, enabling Shoreline to rapidly advance multiple products in parallel.
 
“With more than a decade of proven expertise in cell therapy manufacturing and an established supply chain and logistics infrastructure, Dendreon is well positioned to support Shoreline in manufacturing from Phase I clinical trials through commercialization,” said Maria Cho, vice president of business development and corporate strategy, Dendreon. “We are thrilled to partner with Shoreline to enable the future of cell therapy and change the way serious diseases are treated.”
 
“We are excited to partner with Dendreon, a leader in cell therapy, to manufacture cost-efficient, highly-scalable product candidates,” said Mohammad El-Kalay, senior vice president and head of CMC, Shoreline. “Through our partnership with Dendreon, we are accelerating the commercialization of our next generation NK cell and macrophage products to bring scalable, allogeneic, ‘off the shelf’ therapies to more patients in need.”